Selective estrogen receptor degrader

DRUG CLASS:

Selective estrogen receptor degrader

News alerts, weekly reports and conference planners

Related drugs:

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-0927 Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 3 days (New C3) GDC-0927 Sensitive : C2 Clin Cancer Res - 3d	GDC-0927 Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 3 days GDC-0927 Sensitive : C2 Clin Cancer Res - 3 days - (New C3)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	GDC-0927 Sensitive: C3 – Early Trials Clin Cancer Res - 3 days (New C3) GDC-0927 Sensitive : C3 Clin Cancer Res - 3d	GDC-0927 Sensitive: C3 – Early Trials Clin Cancer Res - 3 days GDC-0927 Sensitive : C3 Clin Cancer Res - 3 days - (New C3)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	AZD9833 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) AZD9833 Sensitive : C3 ASCO 2023 - 1wk	AZD9833 Sensitive: C3 – Early Trials ASCO 2023 - 1 week AZD9833 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	elacestrant Sensitive: A2 - Guideline ASCO.org - 2 weeks (New A2) elacestrant Sensitive : A2 ASCO.org - 2wk	elacestrant Sensitive: A2 - Guideline ASCO.org - 2 weeks elacestrant Sensitive : A2 ASCO.org - 2 weeks - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline ASCO.org - 2 weeks (New A2) fulvestrant Sensitive : A2 ASCO.org - 2wk	fulvestrant Sensitive: A2 - Guideline ASCO.org - 2 weeks fulvestrant Sensitive : A2 ASCO.org - 2 weeks - (New A2)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	enzalutamide capsule + fulvestrant Sensitive: C3 – Early Trials NPJ Breast Cancer - 2 weeks (New C3) enzalutamide capsule + fulvestrant Sensitive : C3 NPJ Breast Cancer - 2wk	enzalutamide capsule + fulvestrant Sensitive: C3 – Early Trials NPJ Breast Cancer - 2 weeks enzalutamide capsule + fulvestrant Sensitive : C3 NPJ Breast Cancer - 2 weeks - (New C3)
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
ESR1 wild-type + HR positive	HER2 Positive Breast Cancer	ESR1 wild-type + HR positive	HER2 Positive Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	fulvestrant Resistant: B - Late Trials fulvestrant Resistant : B	fulvestrant Resistant: B - Late Trials fulvestrant Resistant : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ZN-c5 Sensitive: C2 – Inclusion Criteria ZN-c5 Sensitive : C2	ZN-c5 Sensitive: C2 – Inclusion Criteria ZN-c5 Sensitive : C2
ER mutation	Breast Cancer	ER mutation	Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2
ER D538G	Breast Cancer	ER D538G	Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2
ER Y537N	HER2 Negative Breast Cancer	ER Y537N	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER D538G	HER2 Negative Breast Cancer	ER D538G	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3

Selective estrogen receptor degrader

Selective estrogen receptor degrader

Associations(94)

Associations
(94)